Shares of Veeva Systems (NYSE:VEEV), a company focused on providing cloud solutions to pharmaceutical companies, rose as much as 12% yesterday. Many were left wondering what accounted for such a big jump.
After a little digging, I believe I've found the most likely culprit: a survey released by Veeva itself outlining how outdated many pharmaceutical and life sciences companies are when it comes to clinical data collection. The document also notes the value proposition that Veeva can offer potential clients.
The slideshow below highlights the biggest takeaways from the report, and what they could mean for Veeva moving forward.
Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need to Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
Brian Stoffel owns shares of Veeva Systems. The Motley Fool recommends Salesforce.com. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.